Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Leukemia • Internal Medicine • Hematology
What is your approach to choosing a conditioning regimen for allogeneic transplant in AML?
What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?
Answer from: Medical Oncologist at Academic Institution
Randomized trials in AML and to a lesser degree in MDS have shown that dose intensity is important for long term disease control. Following the guiding principle of trying to optimize the conditioning for each individual patient I use the following guidelines
1 patients less than 60 with HCTC...
Sign in or Register to read more